Devenir membre

Devenir membre

Espace membre

Espace membre



Rencontre Thématique Oncology : Horizon 2030

jeudi 12 mai 2022 | 8h45 - 16h30

Oncology : Horizon 2030
Technologies and models to address tumor heterogeneity for better personalized medicine

Eurobiomed Cluster invites you to its next thematic meeting dedicated to oncology, in partnership with the Occitanie Region, Ad’occ and Toulouse Métropole. This day will address the prospects in oncology by 2030. More specifically, it will focus on innovations in precision medicine and heterogeneity of tumors, themes opening up prospects for more personalized medicine for better patient care.


8:45 : Welcome
9:15 : Opening

  • Michael DANON – President of Eurobiomed
  • Vincent BOUNES, Vice President of Occitanie Region in charge of health
  • Patricia BEZ, Deputy Major of Toulouse Metropole in charge of Health

9:40 : Glioblastoma : an example of tumor heterogeneity and a major medical challenge 
Pr Elizabeth MOYAL – Neuro-oncologist and Head of the radiotherapy department – Institut Universitaire du Cancer – Toulouse Oncopole

10:05 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 1st session

  • Multimodal single cell omics : a technological revolution for fundamental and clinical oncology
    Jean-Jacques FOURNIE, Centre de Recherche en Cancérologie de Toulouse
  • Computational biology approaches to characterise and model the tumour microenvironment
    Vera PANCALDI, Centre de Recherche en Cancérologie de Toulouse
  • Development of NIK modulators for cancer treatment
    Arnaud FOUSSAT, CEO Yukin Therapeutics

11:15 : Coffee Break

11:35 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 2nd session

  • Role of stromal heterogeneity in immunosuppression and resistance to immunotherapy in cancer
    Fatima MECHTA-GRIGORIOU, Institut Curie (by videoconference)
  • Harnessing innate immunity in cancer therapy
    Ariane MOREL, Director R&D – Pharmacology Department, Innate Pharma

12:20 : High-plex tissue imaging: an integrative way to analyze tumor microenvironment contexture and spatial heterogeneity

12:25 : Lunch

14:00 : Current scientific and industrial approaches to address tumor heterogeneity and microenvironment – 3rd session

  • Protein glycosylation and cellular interfaces in cancer biology
    Frédéric BARD, Centre de Recherche en Cancérologie de Marseille
  • What is neutrophil homeostasis telling us on immune checkpoint blockade in NSCLC?
    Julien FAGET, Institut de Recherche en Cancérologie de Montpellier
  • High endothelial venules (HEVs): specialized blood vessels for lymphocyte entry into tumors during cancer immunotherapy
    Jean-Philippe GIRARD, Institut de Pharmacologie et de Biologie Structurale de Toulouse
  • Diag2tec’s tools and models to study the response to new therapeutic agents in hematological malignancies
    Djamila CHEMLAL , PhD Student Diag2tec
  • Microbiomes contribute to tumor microenvironment, progression and treatment responsiveness
    Céline RIBIERE, Microbiome Scientist Vaiomer

15:55 : Oncology at Pierre Fabre – A strategic perspective
Francesco HOFMANN Medical Care R&D Director

16:20 : Closing by Eurobiomed
16:25 : End of the event

Information : Leïla TOUIHRI

Register on line here


Event sponsored by


With the support of the scientific committee


Date :
jeudi 12 mai 2022
Heure :
8h45 - 16h30
Catégorie d’Évènement: